



Northern California Melanoma Center

phone: 415.750.5660 fax: 415.750.4860

Active Clinical Trials – February 2010

Lynn Spitler MD | Robert Weber MD | Ruth Marlin MD | Cecily FitzGerald MD

ADJUVANT THERAPY

Protocol CA184-029 / EORTC 18071: Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group

Protocol DERMA 111482: A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected melanoma

FIRST LINE THERAPY

Protocol R05185426: BRIM 3: A randomized, open-label, controlled, multicenter, Phase III study in previously untreated patients with unresectable Stage IIIc or Stage IV melanoma with V600E BRAF mutation receiving R05185426 or Dacarbazine

Protocol CA033: An open-label, multicenter, Phase III trial of ABI-007 vs Dacarbazine in previously untreated patients with metastatic malignant melanoma

FIRST OR SECOND LINE THERAPY

Protocol 005/05: A randomized Phase 3 clinical trial to evaluate the efficacy and safety of treatment with OncoVEX GM-CSF compared to subcutaneously administered GM-CSF in melanoma patients with unresectable Stage IIIb, IIIc and IV disease

SECOND LINE THERAPY

Protocol 184051/LEU001: GM-CSF and Ipilimumab as second-line therapy in metastatic melanoma, a Phase II study

SECOND LINE THERAPY OR BEYOND

Protocol CA 184045: A multicenter treatment protocol for compassionate use of Ipilimumab (BMS-7340216) monotherapy in subjects with unresectable Stage III or Stage IV melanoma (may also be used as second line therapy) TEMPORARY HOLD

Protocol TH-CR-401: A Phase I, multi-center, open-label, dose-escalation study of safety, pharmacokinetics and anti-tumor activity of TH-302 in patients with advanced solid tumors

Maintenance Protocol (not a clinical trial): IL-2 and GM-CSF for patients who have responded to chemotherapy

OTHER

Protocol CB-SA-01: An exploratory analysis of tumor specific T- Cells in subjects with clinically and histologically diagnosed cancer



St. Mary's Medical Center
A member of CHW

450 Stanyan Street
San Francisco, CA 94117-1079
P (415) 750-5660
W stmarysmedicalcenter.org